Q1 Earnings Forecast for NKTR Issued By Zacks Research

Nektar Therapeutics (NASDAQ:NKTR) – Zacks Research issued their Q1 2027 earnings per share (EPS) estimates for Nektar Therapeutics in a research report issued to clients and investors on Wednesday, April 2nd. Zacks Research analyst K. Das expects that the biopharmaceutical company will post earnings per share of ($0.23) for the quarter. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. Zacks Research also issued estimates for Nektar Therapeutics’ FY2027 earnings at ($1.02) EPS and FY2027 earnings at ($1.02) EPS.

Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Wednesday, March 12th. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.33. Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%. The firm had revenue of $29.18 million during the quarter, compared to analyst estimates of $36.65 million.

Other equities analysts have also issued research reports about the company. Oppenheimer upgraded Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a research note on Friday, March 14th. B. Riley started coverage on Nektar Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $4.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $6.50 target price on shares of Nektar Therapeutics in a research report on Thursday, March 13th. Finally, William Blair reissued a “market perform” rating on shares of Nektar Therapeutics in a report on Thursday, March 13th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Nektar Therapeutics has an average rating of “Buy” and a consensus target price of $4.92.

Nektar Therapeutics Stock Performance

NKTR stock opened at $0.55 on Friday. The firm’s fifty day moving average is $0.82 and its 200 day moving average is $1.03. The firm has a market cap of $102.71 million, a PE ratio of -0.66 and a beta of 0.69. Nektar Therapeutics has a one year low of $0.53 and a one year high of $1.93.

Hedge Funds Weigh In On Nektar Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP raised its stake in Nektar Therapeutics by 10.4% in the 4th quarter. Wellington Management Group LLP now owns 522,409 shares of the biopharmaceutical company’s stock valued at $486,000 after purchasing an additional 49,319 shares during the last quarter. Mackenzie Financial Corp grew its holdings in shares of Nektar Therapeutics by 801.4% during the fourth quarter. Mackenzie Financial Corp now owns 469,769 shares of the biopharmaceutical company’s stock worth $437,000 after buying an additional 417,651 shares in the last quarter. US Asset Management LLC purchased a new stake in shares of Nektar Therapeutics during the fourth quarter worth $31,000. Woodline Partners LP raised its position in shares of Nektar Therapeutics by 187.3% in the fourth quarter. Woodline Partners LP now owns 4,974,512 shares of the biopharmaceutical company’s stock valued at $4,626,000 after buying an additional 3,242,841 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new position in shares of Nektar Therapeutics in the fourth quarter worth about $130,000. Hedge funds and other institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.